Mayne Protocol 18-ICH-001: A Phase 2 randomized, multi-center, double-blind, vehicle controlled, 12 week, safety, efficacy & systemic exposure study followed by a 12 week open-label extension of CD5789 in adults and adolescents with autosomal recessive ichthyosis with lamellar scale. | Learn More » | Request to Join This Study »